42 results on '"Trajkovic-Arsic, Marija"'
Search Results
2. Functional biomarkers derived from computed tomography and magnetic resonance imaging differentiate PDAC subgroups and reveal gemcitabine-induced hypo-vascularization
3. Fibroblast Activation Protein Inhibitor Theranostics: Preclinical Combination Treatment
4. Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer
5. Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma
6. Fibroblast Activation Protein-Directed Imaging Outperforms 18F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial.
7. Histology-Based Radiomics for [18F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer.
8. Development of a LRRC15-Targeted Radio-Immunotheranostic Approach to Deplete Pro-tumorigenic Mechanisms and Immunotherapy Resistance
9. Pancreatic cancer acquires resistance to MAPK pathway inhibition by clonal expansion and adaptive DNA hypermethylation
10. Minimally invasive determination of PDAC subtype and therapy-induced subtype switch by means of circulating cell-free RNA
11. MAPK-pathway inhibition mediates inflammatory reprogramming and sensitizes tumors to targeted activation of innate immunity sensor RIG-I
12. Author Correction: Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC
13. Hyperpolarized 13C pyruvate magnetic resonance spectroscopy for in vivo metabolic phenotyping of rat HCC
14. Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma
15. The long non-coding RNA HOTAIRM1 promotes tumor aggressiveness and radiotherapy resistance in glioblastoma
16. Fibroblast Activation Protein-Targeted Photodynamic Therapy of Cancer-Associated Fibroblasts in Murine Models for Pancreatic Ductal Adenocarcinoma
17. Fibroblast Activation Protein-Targeting Minibody-IRDye700DX for Ablation of the Cancer-Associated Fibroblast with Photodynamic Therapy
18. Superior Tumor Detection for68Ga-FAPI-46 Versus18F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma
19. Figure S3 from LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
20. Supplementary Data DS1 from LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
21. Supplement from Co-clinical Assessment of Tumor Cellularity in Pancreatic Cancer
22. Data from Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting
23. Figure S2 from Notch-Induced Myeloid Reprogramming in Spontaneous Pancreatic Ductal Adenocarcinoma by Dual Genetic Targeting
24. Supplementary Figure S3 from Selective In Vivo Imaging of Syngeneic, Spontaneous, and Xenograft Tumors Using a Novel Tumor Cell–Specific Hsp70 Peptide-Based Probe
25. Data from Selective In Vivo Imaging of Syngeneic, Spontaneous, and Xenograft Tumors Using a Novel Tumor Cell–Specific Hsp70 Peptide-Based Probe
26. Supplemental Methods, Figure Legends from Selective In Vivo Imaging of Syngeneic, Spontaneous, and Xenograft Tumors Using a Novel Tumor Cell–Specific Hsp70 Peptide-Based Probe
27. LAMC2 regulates key transcriptional and targetable effectors to support pancreatic cancer growth
28. Dose‐dependent expression of GFI1 alters metabolism in the haematopoietic progenitors and MLL::AF9‐induced leukaemic cells.
29. LAMC2 Regulates Key Transcriptional and Targetable Effectors to Support Pancreatic Cancer Growth
30. Additional file 1 of Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma
31. Additional file 2 of Functional noninvasive detection of glycolytic pancreatic ductal adenocarcinoma
32. Superior Tumor Detection for 68Ga-FAPI-46 Versus 18F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma.
33. Functional non-invasive detection of glycolytic pancreatic ductal adenocarcinoma
34. Epigenetic plasticity via adaptive DNA hypermethylation and clonal expansion underlie resistance to oncogenic pathway inhibition in pancreatic cancer
35. Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice
36. Is metabolism the magic bullet for targeted cancer therapy?
37. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma
38. A FAP-targeting minibody-IRDye700DX for photodynamic therapy of the cancer associated fibroblast.
39. Fibroblast activation protein inhibitor (FAPI) Theranostics: Preclinical combination treatment
40. Fibroblast Activation Protein-Directed Imaging Outperforms 18 F-FDG PET/CT in Malignant Mesothelioma: A Prospective, Single-Center, Observational Trial.
41. Histology-Based Radiomics for [ 18 F]FDG PET Identifies Tissue Heterogeneity in Pancreatic Cancer.
42. Superior Tumor Detection for 68 Ga-FAPI-46 Versus 18 F-FDG PET/CT and Conventional CT in Patients with Cholangiocarcinoma.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.